Results 51 to 60 of about 4,378 (208)

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach

Frontiers in Medicine, 2022
There are currently four anti-cancer medicinal products approved for a tissue-agnostic indication. This is an indication based on a common biological characteristic rather than the tissue of origin. To date, the regulatory experience with tissue-agnostic
Jorn Mulder, Odile C. van Stuijvenberg, Paula B. van Hennik, Emile E. Voest, Emile E. Voest, Anna M. G. Pasmooij, Violeta Stoyanova-Beninska, Anthonius de Boer, Anthonius de Boer   +8 more
doaj   +1 more source

Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene

Frontiers in Oncology, 2023
Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies.
Catherine Cervi, Catherine Cervi, Zoltán Sápi, Gábor Bedics, Gábor Bedics, Erik Zajta, Erik Zajta, Lajos Hegyi, Lajos Hegyi, Judit Pápay, Katalin Dezső, Edit Varga, Katalin Mudra, Csaba Bödör, Csaba Bödör, Monika Csóka   +15 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, EarlyView.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Frontiers in Oncology, 2022
Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors.
Chiara Lazzari, Lorenza Pecciarini, Claudio Doglioni, Federica Pedica, Ana Maria Samanes Gajate, Alessandra Bulotta, Vanesa Gregorc, Maria Giulia Cangi   +7 more
doaj   +1 more source

Precision medicine in cutaneous melanoma—A comprehensive review

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley   +1 more source

Peripheral Nerves in Cancer: Regulatory Roles and Therapeutic Strategies

MedComm, Volume 7, Issue 2, February 2026.
The interaction between cancer cells and peripheral nerves: (1) tumor cells could induce the growth of new neural axons and constructing a neural fiber network within the tumor tissue through secreting nerve growth factors; (2) nerve‐derived bioactive molecules can induce perineural invasion of tumor and regulate the malignant phenotype of tumor, such ...
Yan Fu, Zhi‐Shan Ge, Qing‐Yue Cao, Zi‐Han Li, An Zhang, Hai‐Dong Zhu, Gao‐Jun Teng   +6 more
wiley   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, Volume 117, Issue 1, Page 156-168, January 2026.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source